A Star Is Born? HERCULES Data Shine At ASH For Ablynx's Caplacizumab
Executive Summary
Strong Phase III HERCULES data mean Ablynx's caplacizumab is likely to sail through regulatory proceedings next year, becoming the first approved therapy for the rare blood disease, acquired thrombotic thrombocytopenic purpura.
You may also be interested in...
The Year's Clinical Trials In Review: Big Hits In 2017
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.
Caterpillar To Butterfly? Ablynx Says Caplacizumab Data Transformational
Belgian Nanobody drug developer Ablynx says it will be transformed by positive Phase III topline HERCULES data on caplacizumab for treating the rare blood-clotting disorder, acquired TTP.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.